Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC10972549 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature